Top

Published in:

01-04-2005 | Original Article

Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases

Authors: Sevil Kamali, Ayse Cefle, Mehmet Sayarlioglu, Ahmet Gul, Murat Inanc, Lale Ocal, Orhan Aral, Meral Konice

Published in: Rheumatology International | Issue 3/2005

Abstract

We aimed to investigate the efficacy and safety profile of high-dose intravenous immunoglobulin (HD-IVIG) therapy in patients with severe systemic lupus erythematosus (SLE), inflammatory muscle disease (IMD), Wegener’s granulomatosis (WG), and/or concurrent infection who failed to respond to standard therapies. We evaluated the records of eight patients with SLE, eight with IMD, and four with WG who were treated with HD-IVIG (2 g/kg per month for 1–12 months) for active disease in 19 patients and concurrent infection in three (mycobacterial in two with SLE and cytomegaloviral in one with WG). Systemic lupus erythematosus disease activity index (SLEDAI) scores before and after HD-IVIG were statistically analysed. Remission was achieved in 14 cases (70%). The SLEDAI scores significantly decreased in patients with SLE (P=0.02). No serious side effect was observed. High-dose IVIG may be used as an adjunctive treatment in connective tissue diseases that do not respond to standard therapies or as alternative treatment for patients with concurrent severe infections or for whom immunosuppressives are contraindicated.

Imbach P, Wagner H, Berchtold W et al (1985) Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 2:464CrossRefPubMed

Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J et al (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324:1633–1639PubMed

Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM (1991) Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 91:169–172PubMed

Dalakas MC (1991) Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 325:1487–1498

Choy EH, Isenberg DA (2002) Treatment of dermatomyositis and polymyositis. Rheumatology 411:7–13CrossRef

Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, Maisonobe T, Eymard B, Herson S (2002) Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 46:467–474CrossRefPubMed

Collet E, Dalac S, Maerens B, Courtois JM, Izac M, Lambert D (191994) Juvenile dermatomyositis: treatment with intravenous gammaglobulin. Br J Dermatol 130:231–234

Levy Y, Sherer Y, Ahmed A, Langevitz P, George J et al (1999) A study of 20 patients with intravenous immunoglobulin—clinical and serologic response. Lupus 8:705–712CrossRefPubMed

Levy Y, Sherer Y, George J, Rovensky J, Lukac J et al (2000) Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum 29:321–327PubMed

10.

Palla R, Cirami C, Bionda A et al (1986) High dose intravenous gammaglobulin for membranous nephropathy. Clin Nephrol 26:314

11.

Boletis JN, Ioannidis JPA, Boki KA, Moutsopoulos HM (1999) Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 354:569–570CrossRefPubMed

12.

Carreras LO, Perez GN, Vega HR, Casavilla F (1988) Lupus anticoagulant and recurrent fatal loss: successful treatment with gammaglobulin. Lancet 2:393–394CrossRef

13.

Sherer Y, Levy Y, Shoenfeld Y (2000) Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology 39:421–426CrossRefPubMed

14.

Branch D, Ware MD, Peaceman AM et al (2000) A multicenter, placebo controlled pilot study of intravenous treatment of antiphospholipid syndrome during pregnancy. Am J Obstet Gynecol 182:122–127PubMed

15.

Jayne DRW, Lockwood CM (1996) Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 35:1150–1153CrossRefPubMed

16.

Jayne DRW, Chapel H, Adu D, Misbah S, O’Donoghue D, Scott D (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93:433–49CrossRefPubMed

17.

Permal S, Wechsler B, Cabane J, Perrot S, Blum L, Imbert JC (1995) Treatment of Still disease in adults with intravenous immunoglobulins. Rev Med Interne 16:250–254CrossRefPubMed

18.

Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747–755PubMed

19.

Tan EM (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMed

20.

Leavitt RY et al (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33:1101–1107PubMed

21.

Dalakas MC (1988) A classification of polymyositis and dermatomyositis. In: Dalakas MC (ed) Polymyositis and dermatomyositis. Butterworth, Boston, pp 1–16

22.

Pyne D, Ehrenstein M, Morris V (2002) The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases. Rheumatology 41:367–374CrossRefPubMed

23.

Maier WP, Gordon DS, Howard RF, Saleh MN, Miller SB et al (1990) Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum 33:1233–1239PubMed

24.

Jacobs P, Wood L (1989) The comparison of gammaglobulin to steroids in treating adult immune thrombocytopenia: an interim analysis. Blut 59:92–95PubMed

25.

Sherer Y, Levy Y, Langevitz P, Lorber M, Fabrizzi F, Shoenfeld Y (1999) Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol 18:170–173CrossRefPubMed

26.

Lafferty TE, Smith JB, Schuster SJ, De Horatius RJ (1997) Treatment of acquired factor VIII inhibitor using intravenous immunoglobulin in two patients with systemic lupus erythematosus. Arthritis Rheum 40:775–778PubMed

27.

Aharon A, Levy Y, Bar-Dayan Y, Afek A, Zandman-Goddard G, Skurnik Y, Fabrizzi F, Shoenfeld Y (1997) Successful treatment of early secondary myelofibrosis in SLE with IVIG. Lupus 6:408–411PubMed

28.

Kurth R, Haas WH (2002) Epidemiology, diagnostic possibilities, and treatment of tuberculosis. Ann Rheum Dis 61 [Suppl 2]:ii59–ii61

29.

Dalakas MC (1998) Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 51 [6 Suppl 5]:S37–S45

30.

Hamilos DL, Christensen J (1991) Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. J Allergy Clin Immunol 88:823–824PubMed

31.

Levy Y, Sherer Y, George J, Langevitz P, Ahmed A, Bar-Dayan Y, Fabrizzi F, Terryberry J, Peter J, Shoenfeld Y (1999) Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol 119:231–238CrossRefPubMed

32.

Epstein JS, Gaines A, Kapit R, Pierce R, Potter R, Varricchio F (1999) Important drug information: immune globulin intravenous (human). Int J Trauma Nurs 5:139–140PubMed

33.

Hashkes PJ, Lovell DJ (1996) Vasculitis in systemic lupus erythematosus following intravenous immunoglobulin therapy. Clin Exp Rheumatol 14:673–675PubMed

Title: Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases
Authors: Sevil Kamali
Ayse Cefle
Mehmet Sayarlioglu
Ahmet Gul
Murat Inanc
Lale Ocal
Orhan Aral
Meral Konice
Publication date: 01-04-2005
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 3/2005
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-003-0422-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2005

Radon therapy for the treatment of rheumatic diseases—review and meta-analysis of controlled clinical trials

Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder?

Development of multiple malignancies after immunosuppression in a patient with Wegener’s granulomatosis

Hydrotherapy, balneotherapy, and spa treatment in pain management

A case of idiopathic hypertrophic cranial pachymeningitis manifested only by positive rheumatoid factor and abnormal findings of the anterior falx

Proposal for a sonographic classification of target joints in rheumatoid arthritis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials